22.22 USD
↘ 0.59 (2.57%)LIVE (AS OF 11:43 AM EDT)
QURE is currently priced at $22.22. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Oct 5, 2026.
Open?$23.02
High?$23.10
Low?$21.22
Prev. Close?$22.80
Volume?1.1M
Avg. Volume?2.7M
VWAP?$21.84
Rel. Volume?0.41x
Bid / Ask
Bid?$21.42 × 100
Ask?$22.15 × 300
Spread?$0.73
Midpoint?$21.79
Valuation & Ratios
Market Cap?1.6B
Shares Out?69.4M
Float?66.1M
Float %?95.4%
P/E Ratio?N/A
P/B Ratio?4.88
EPS?-$3.64
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Themes
Address
PAASHEUVELWEG 25A
AMSTERDAM, 1105 BP
Phone: 1-339-970-7000
AMSTERDAM, 1105 BP
Phone: 1-339-970-7000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?2
Momentum?35
Short Sent.?54
Piotroski F-Score?4/9Mixed
Altman Z-Score?-0.34Distress
Confidence?62%Moderate
Short InterestHigh
Short % of Float?15.00%High
Short Interest?9.9M
Days to Cover?8.1
Free Float66.1M
Avg Daily Volume1.2M
Settlement Date2026-09-15
Financial Health
Current Ratio?10.01Strong
Quick Ratio?10.01Strong
Cash Ratio?4.96Strong
Debt/Equity?0.15Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?4.88FAIR▾
Peers100
S&P38
P/S?84.70HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-7.0CHEAP▾
S&P97
EV/Sales?65.27HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-77.8%WEAK▾
S&P3
ROA?-25.6%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-161452000
Enterprise Value?$1.2B
Fundamentals ratios updated end of day